|
|
|
| Research progress in the treatment of non-alcoholic fatty liver disease by fecal microbiota transplantation |
| LIU Yincong MA Xiuying ZHANG Yuting LUO Jinbo XIAO An WANG Wenxue GENG Jiawei |
Affiliated Hospital of Kunming University of Science and Technology the First People’s Hospital of Yunnan Province, Yunnan Province, Kunming 650500, China
|
|
|
|
Abstract Non-alcoholic fatty liver disease is one of the most common chronic liver diseases, and the prevalence rate is increasing year by year worldwide, and there is no specific treatment. Recent years’ studies have shown that intestinal flora imbalance can promote the occurrence and development of non-alcoholic fatty liver disease through the enteric-liver axis, and fecal microbiota transplantation can reconstruct intestinal flora in patients with non-alcoholic fatty liver disease, improve hepatocyte steatosis, and reduce liver inflammation. In this paper, the possible mechanism of fecal microbiota transplantation in the treatment of non-alcoholic fatty liver disease, the current domestic and foreign preclinical, and clinical research progress and existing problems are summarized, to provide reference for the future clinical treatment of fecal microbiota transplantation in non-alcoholic fatty liver disease.
|
|
|
|
|
|
[1] Riazi K，Azhari H，Charette JH，et al. The prevalence and incidence of NAFLD worldwide：a systematic review and meta- analysis [J]. Lancet Gastroenterol Hepatol，2022，7（9）:851- 861.
[2] Powell EE，Wong VW，Rinella M. Non-alcoholic fatty liver disease [J]. Lancet（London，England），2021，397（10290）：2212-2224.
[3] The Lancet Gastroenterology Hepatology. Headway and hurdles in non-alcoholic fatty liver disease [J]. Lancet Gastroenterol Hepatol，2020，5（2）：93.
[4] Hu H，Lin A，Kong M，et al. Intestinal microbiome and NAFLD：molecular insights and therapeutic perspectives [J]. J Gastroenterol，2020，55（2）：142-158.
[5] Aron-Wisnewsky J，Vigliotti C，Witjes J，et al. Gut microbiota and human NAFLD：disentangling microbial signatures from metabolic disorders [J]. Nat Rev Gastroenterol Hepatol，2020，17（5）：279-297.
[6] Aron-Wisnewsky J，Warmbrunn MV，Nieuwdorp M，et al. Nonalcoholic Fatty Liver Disease：Modulating Gut Microbiota to Improve Severity？[J]. Gastroenterology，2020，158（7）：1881-1898.
[7] Lechner S，Yee M，Limketkai BN，et al. Fecal Microbiota Transplantation for Chronic Liver Diseases：Current Understanding and Future Direction [J]. Dig Dis Sci，2020，65（3）：897-905.
[8] Scorletti E，Afolabi PR，Miles EA，et al. Synbiotics Alter Fecal Microbiomes，But Not Liver Fat or Fibrosis，in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease [J]. Gastroenterology，2020，158（6）：1597-1610.
[9] Zheng L，Ji YY，Wen XL，et al. Fecal microbiota transplantation in the metabolic diseases：Current status and perspectives [J]. World J Gastroenterol，2022，28（23）：2546-2560.
[10] Ke S，Weiss ST，Liu YY. Rejuvenating the human gut microbiome [J]. Trends Mol Med，2022，28（8）：619-630.
[11] Bauer KC，Littlejohn PT，Ayala V，et al. Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis：Exploring an Undernutrition Perspective [J]. Gastroenterology，2022，162（7）：1858-1875.e2.
[12] 王玉莹，石汉平，饶本强.粪菌移植的临床操作与应用[J].肿瘤代谢与营养电子杂志，2022，9（3）：390-395.
[13] Ooijevaar RE，Terveer EM，Verspaget HW，et al. Clinical Application and Potential of Fecal Microbiota Transplantation [J]. Annu Rev Med，2019，70：335-351.
[14] Abenavoli L，Procopio AC，Scarpellini E，et al. Gut microbiota and non-alcoholic fatty liver disease [J]. Minerva Gastroenterol，2021，67（4）：339-347.
[15] Quesada-Vázquez S，Aragonès G，Del Bas JM，et al. Diet，Gut Microbiota and Non-Alcoholic Fatty Liver Disease：Three Parts of the Same Axis [J]. Cells，2020，9（1）：176.
[16] Wiest R，Albillos A，Trauner M，et al. Targeting the gut-liver axis in liver disease [J]. J Hepatol，2017，67（5）：1084-1103.
[17] Albillos A，de Gottardi A，Rescigno M. The gut-liver axis in liver disease：Pathophysiological basis for therapy [J]. J Hepatol，2020，72（3）：558-577.
[18] Milosevic I，Vujovic A，Barac A，et al. Gut-Liver Axis，Gut Microbiota，and Its Modulation in the Management of Liver Diseases：A Review of the Literature [J]. Int J Mol Sci，2019，20（2）：395.
[19] Bessone F，Razori MV，Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression [J]. Cell Mol Life Sci，2019，76（1）：99-128.
[20] Gupta M，Krishan P，Kaur A，et al. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD [J]. Inflamm Res，2021，70（7）：765-776.
[21] Burz SD，Monnoye M，Philippe C，et al. Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease（NAFLD）[J]. Microorganisms，2021，9（1）：199.
[22] Zhou D，Pan Q，Shen F，et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota [J]. Sci Rep，2017，7（1）：1529.
[23] García-Lezana T，Raurell I，Bravo M，et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis [J]. Hepatology，2018，67（4）：1485-1498.
[24] Craven L，Rahman A，Nair Parvathy S，et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability：A Randomized Control Trial [J]. Am J Gastroenterol，2020，115（7）：1055-1065.
[25] Xue L，Deng Z，Luo W，et al. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease：A Randomized Clinical Trial [J]. Front Cell Infect Microbiol，2022，12：759306.
[26] Wu X，Dai M，Buch H，et al. The recognition and attitudes of postgraduate medical students toward fecal microbiota transplantation：a questionnaire study [J]. Therap Adv Gastroenterol，2019，12：1756284819869144.
[27] Marcella C，Cui B，Kelly CR，et al. Systematic review：the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020 [J]. Aliment Pharmacol Ther，2021，53（1）：33-42.
[28] De Filipp Z，Bloom PP，Torres Soto M，et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant [J]. N Engl J Med，2019，381（21）：2043-2050.
[29] 中华医学会肠外肠内营养学分会，中国国际医疗保健促进交流会加速康复外科分会，中国微生态治疗创新联盟，等.菌群移植标准化方法学的建立与临床应用中国专家共识[J].中华胃肠外科杂志，2020，23（Z1）：5-13.
[30] 徐浩杰，王璐，王诗童，等.粪菌移植技术的医学伦理问题思考[J].医学与哲学，2021，42（17）：23-27.
[31] 何植，张发明.中华粪菌库的原则、方案和风险管理[J].胃肠病学，2017，22（4）：193-198. |
|
|
|
